--- title: "MFS 高收益市政信託宣佈了要約收購的最終結果" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/285991545.md" description: "MFS High Yield Municipal Trust 已完成其收購要約，接受了 12,746,391 股，約佔總流通股的 50%。該要約於 2026 年 5 月 5 日到期，約 91.38% 的投標股份以淨資產價值的 99% 被接受支付，摺合每股 3.75 美元。該基金由 MFS Investment Management 管理，管理資產總額為 6507 億美元" datetime: "2026-05-11T20:15:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285991545.md) - [en](https://longbridge.com/en/news/285991545.md) - [zh-HK](https://longbridge.com/zh-HK/news/285991545.md) --- # MFS 高收益市政信託宣佈了要約收購的最終結果 BOSTON--(BUSINESS WIRE)-- MFS® High Yield Municipal Trust (the “Fund”) announced today that, in accordance with its tender offer for up to 50% of the Fund’s outstanding common shares (the “Shares”), which expired at 5:00 P.M., Eastern Time, on May 5, 2026, the Fund has accepted 12,746,391 Shares, representing 50% of Shares, for payment on or about May 11, 2026. A total of 13,949,629.03 Shares were properly tendered and not withdrawn by May 5, 2026, the final date for withdrawals. Therefore, on a prorated basis, approximately 91.38% of the Shares so tendered by each shareholder have been accepted for payment. The purchase price of properly tendered Shares is 99% of the Fund’s net asset value (“NAV”) per Share calculated as of the close of regular trading on the New York Stock Exchange (“NYSE”) on May 5, 2026, which is equal to $3.75 per Share. The Fund’s information agent for the tender offer is Georgeson LLC and the depositary agent for the tender offer is Computershare Trust Company, N.A. Any questions with regard to the tender offer may be directed to the information agent toll-free at 1-866-316-3922. **About the Fund **The Fund is a closed-end investment company product advised by MFS Investment Management. Closed-end funds, unlike open-end funds, are not continuously offered. Except pursuant to a tender offer, common shares of the Fund are only available for purchase/sale on the NYSE at the current market price. Shares may trade at a discount to NAV. Shares of the Fund are not FDIC-insured and are not deposits or other obligations of, or guaranteed by, any bank. Shares of the Fund involve investment risk, including possible loss of principal. For more complete information about the Fund, including risks, charges, and expenses, please see the Fund's annual and semi-annual shareholder reports or contact your financial adviser. **About MFS Investment Management **In 1924, MFS launched the first U.S. open-end mutual fund, opening the door to the markets for millions of everyday investors. Today, as a full-service global investment manager serving financial advisors, intermediaries, and institutional clients, MFS still serves a single purpose: to create long-term value for clients by allocating capital responsibly. That takes our powerful investment approach combining collective expertise, thoughtful risk management and long-term discipline. Supported by our culture of shared values and collaboration, our teams of diverse thinkers actively debate ideas and assess material risks to uncover what we believe are the best investment opportunities in the market. As of April 30, 2026, MFS manages $650.7 billion in assets on behalf of individual and institutional investors worldwide. Please visit mfs.com for more information. **MFS Investment Management 111 Huntington Ave., Boston, MA 02199** 68322.1 View source version on businesswire.com: https://www.businesswire.com/news/home/20260511248505/en/ Source: MFS Investment Management ### 相關股票 - [CXE.US](https://longbridge.com/zh-HK/quote/CXE.US.md) - [CMU.US](https://longbridge.com/zh-HK/quote/CMU.US.md) - [CPU.AU](https://longbridge.com/zh-HK/quote/CPU.AU.md) ## 相關資訊與研究 - [AXT 公司宣佈推遲 2026 年股東年度會議 | AXTI 股票新聞](https://longbridge.com/zh-HK/news/286555225.md) - [谷歌 Pichai：Gemini APP 月活用户數一年翻倍，至超過 9 億](https://longbridge.com/zh-HK/news/286948236.md) - [Onto Innovation 公司定價擴大至 13 億美元的 2031 年到期可轉換債券](https://longbridge.com/zh-HK/news/286875569.md) - [Noble 收到法院關於安排的最終命令](https://longbridge.com/zh-HK/news/286904057.md) - [B7-H3 成為腫瘤學領域最熱門的抗原，一種 NK 結合劑已進入臨牀試驗](https://longbridge.com/zh-HK/news/286806955.md)